Pfizer stock and other vaccine shares tumbled Friday morning after Trump picked Kennedy to lead the Department of Health and ...

Findings highlight the Pfizer-BioNTech vaccine’s role in preventing MIS-C, a rare post-COVID inflammatory syndrome in ...

Shares of vaccine makers fell as President-elect Donald Trump nominated Robert F. Kennedy Jr., a prominent vaccine skeptic, ...

The selection of vaccine sceptic Robert F Kennedy Jr by US President-elect Donald Trump to head the Department of Health and ...

With the help of TBWA\Chiat\Day New York, pharma giant Moderna is demystifying mRNA science for the average consumer. This ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2 ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

German drugmaker BioNTech on Monday lowered its guidance for full-year revenue, citing COVID-19 uptake and price levels, inventory write-downs and Pfizer charges.

Shares of prominent vaccine makers plunged Thursday after President-elect Donald Trump announced his pick of Robert F.

Jefferies analyst Akash Tewari maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $150.00.